Inside Endpoints News: How to Pitch Endpoints News Journalists & Win Product Coverage
Endpoints News is not a generalist tech blog with a health vertical bolted on. It is a biopharma business newspaper — one that treats science, capital, and regulation as a single, interlocking market. To earn coverage there, Endpoints News journalists must see your product as something that changes how drugs get made, tested, approved, or paid for.
This guide is an editorial intelligence briefing for founders, heads of product, and comms leads pitching the intersection of software and therapeutics.
Editorial Focus & The Technology News Cycle at Endpoints News#
Endpoints built its reputation on velocity inside biopharma's most consequential conversations: FDA decisions, clinical readouts, deal terms, pricing scrutiny, and executive churn.
The "technology" beat here is not consumer SaaS. It is the tooling layer of life sciences — AI-driven discovery platforms, clinical trial infrastructure, real-world evidence engines, lab automation, regulatory-grade data systems, and manufacturing software.
💡 Editorial Pro Tip: Frame your product in the vocabulary of drug development risk reduction, not in the vocabulary of developer productivity. Endpoints readers ask "does this make a trial cheaper, faster, or more likely to succeed?" — not "is the DX delightful?"
News cycles at Endpoints run on two clocks: the regulatory calendar (PDUFA dates, advisory committees, FDA guidance drops) and the earnings/financing calendar (JPMorgan week, Q2 biotech IPO windows, Series A/B cadence). Align your announcement to one of them.
There is no single "tech editor" gatekeeping everything. Endpoints News reporters are specialists with defined territories, and misrouting a pitch costs you the story.
Regulatory and FDA-adjacent products belong with the regulatory beat. Financing rounds, M&A, and venture deals go to the money desk. Commercial, marketing, and market-access software goes to the commercial beat.
| Pitch Angle | Receptivity at Endpoints News | Key Requirement |
|---|---|---|
| AI discovery platform with validated hit-rate data | High | Peer-reviewed or reproducible benchmark set |
| Clinical trial software / decentralized trial infra | High | Named pharma or CRO customer already deployed |
| Series A/B raise with named investors | High | Round size, lead investor, use-of-proceeds specifics |
| Regulatory-grade data or FDA-facing tooling | Very High | Clear regulatory pathway relevance |
| General "healthcare AI" positioning | Low | Needs a specific, falsifiable claim |
| Consumer wellness app | Very Low | Not core to the biopharma reader |
Beat specialists reward specificity. A pitch sent to the wrong desk reads as evidence you have not read the publication — a near-automatic delete.
Accessing the Verified Endpoints News Journalists Database for Targeted Pitches#
Endpoints' newsroom is small, senior, and high-output. That makes routing precision more valuable than volume. A structured Endpoints News journalists database lets you match beat, byline history, and recent article cadence before you write a single word.
The same discipline applies to an Endpoints News reporters database: filter by beat tag, then by recency of publication. A reporter who has published three pieces on clinical trial tech in six weeks is a live target; one who moved desks is a wasted send.
⚠️ Common Mistake: Blasting all twenty-plus contacts with an identical email. Endpoints staff talk to each other daily. Duplicate pitches across the newsroom signal a PR spam operation and can get your domain filtered.
Work from a curated Endpoints News journalists list that tracks beat ownership, not just names. Refresh quarterly.
Reaching Tech Reporters: Direct Contacts and Verification Ethics#
Verification is the difference between a working Endpoints News reporters list and a bounce-heavy spreadsheet. Before any send, confirm the reporter still covers your beat and that the address is current.
A Endpoints News journalists list built from public bylines, masthead pages, and verified social profiles will outperform any scraped export. Treat Endpoints News journalists contacts as perishable inventory — newsroom turnover is real.
💡 Editorial Pro Tip: Cross-reference any Endpoints News reporters contacts against the reporter's most recent byline date. If the last article is older than 90 days, confirm the beat assignment before pitching.
On Endpoints News journalists emails and Endpoints News reporters emails: use only business addresses published by the outlet or confirmed through legitimate correspondence. Never infer patterns from a single observed address and mass-generate variants.
A short, factual verification email — "Are you still covering clinical trial technology?" — takes ninety seconds and protects your sender reputation.
What Moves the Needle: Benchmarks, Demos, and Traction Metrics#
Endpoints readers are investors, BD executives, and clinical operators. They discount narrative and price data.
If you claim a model improves trial enrollment prediction, publish the AUC, the cohort size, and the data provenance. If you claim speed, give wall-clock numbers on a named, auditable workflow.
What survives editorial scrutiny:
- Reproducible benchmarks with dataset, code, and evaluation protocol disclosed.
- A live technical demo — even a recorded one — showing the actual product, not a slide.
- Named customers with permission to be quoted.
- Regulatory or reimbursement milestones: 510(k) clearance, CLIA certification, CMS coverage pathway.
What gets cut: "revolutionary," "industry-leading," unnamed pilots, and charts without axes.
Developer adoption matters here in a specific way — an open-source library or API with visible usage inside pharma engineering teams is a stronger story than a marketing claim. Show the GitHub activity, the SDK install curve, the API call volume.
Founder engineering credentials are a legitimate hook. Endpoints has consistently profiled technical founders who built the platform themselves — the credibility of the builder is part of the story.
The Embargo Playbook: Timing, Exclusives, and Pitch Subject Lines#
Endpoints is a competitive newsroom. Exclusives are currency, and embargo discipline is non-negotiable.
Offer a genuine exclusive — one outlet, first publish, 24 to 48 hours ahead. Never offer an "exclusive" to three publications; the resulting retraction is permanent.
| Timing Window | Best For | Embargo Rule |
|---|---|---|
| Monday 6–8 a.m. ET | Financing rounds, product launches | 48-hour embargo, single outlet |
| Tuesday–Thursday a.m. | Benchmarks, API releases, partnerships | 24-hour embargo |
| Friday afternoon | Avoid — low readership | Not recommended |
| During JPMorgan Healthcare week | Deals, strategic partnerships | Coordinate weeks ahead |
| FDA decision weeks | Regulatory-adjacent tooling | Ride the news cycle, don't compete |
Subject lines should read like a headline, not a press release title. Include the number: dollar amount, percentage improvement, or cohort size.
⚠️ Common Mistake: Breaking your own embargo by pre-posting to LinkedIn. Editors track this, and it will end the relationship.
Field-Tested 120-Word Pitch Template for Endpoints News Reporters#
Subject: EMBARGO [Date]: [Company] raises $[X]M to [Mission]
Hi [Name],
[Company] raised a $[X]M Series [A/B] led by [Investor], with participation from [Investor]. We build [one-sentence product description] for [specific pharma/CRO customer segment].
The traction number: [X] trial sites / [X] API calls / [X]% reduction in [specific metric], measured against [baseline]. Customer [Name, Title] at [Company] can speak on record.
We are publishing a reproducible benchmark on [date]: [dataset], [method], [result]. Code and evaluation harness are public.
Founder [Name] is a [PhD/engineer] who previously built [system]. Available for a technical demo any day this week.
Exclusive offered to Endpoints until [date/time ET].
[Name] | [Title] | [Phone]
Streamlining Founder PR Workflows with Pytch#
Most founder PR failures are routing failures. The story is strong; the delivery is scattershot.
Pytch centralizes your media database — beat tags, byline recency, verification dates, and embargo history in one workflow — so the Endpoints News journalists database you maintain stays current and segmented.
That means fewer sends, better targeting, and a defensible record of who received what, when, and under which embargo. In a newsroom that rewards precision, that operational discipline is the pitch.